The U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) announced they would purchase an additional supply of the casirivimab and imdevimab antibody cocktail for use by non-hospitalized COVID-19 patients.
The US government has said it will provide these doses at no cost to patients, though healthcare facilities may charge fees related to administration.
Read More
